PYLERA

This brand name is authorized in Austria, Estonia, Spain, France, Poland, Tunisia, United States

Active ingredients

The drug PYLERA contains a combination of these active pharmaceutical ingredients (APIs):

1 Tripotassium dicitrato bismuthate
UNII R3O80H60KX - BISMUTH SUBCITRATE POTASSIUM

Under the effect of gastric acid, a precipitate is formed from tripotassium dicitrato bismuthate, which adheres primarily to the ulcerated area and inhibits the activity of pepsin. Tripotassium dicitrato bismuthate contributes to the healing of a high percentage of gastric and duodenal ulcers.

Read about Tripotassium dicitrato bismuthate
2 Methronidazole
UNII 140QMO216E - METRONIDAZOLE

Metronidazole is an anti-infectious drug belonging to the pharmacotherapeutic group of nitroimidazole derivatives, which have effect mainly on strict anaerobes. This effect is probably caused by interaction with DNS and different metabolites.

Read about Methronidazole
3 Tetracycline
UNII P6R62377KV - TETRACYCLINE HYDROCHLORIDE

Tetracyclines are taken up into sensitive bacterial cells by an active transport process. Once within the cell they bind reversibly to the 30S subunit of the ribosome, preventing the binding of aminoacyl transfer RNA and inhibiting protein synthesis and hence cell growth.

Read about Tetracycline

Medication package inserts

Below package inserts are available for further reading:

Title Information Source Document Type  
PYLERA Capsule FDA, National Drug Code (US) MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
A02BD08 A Alimentary tract and metabolism → A02 Drugs for acid related disorders → A02B DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) → A02BD Combinations for eradication of Helicobacter pylori
Discover more medicines within A02BD08

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: EE Ravimiamet Identifier(s): 1688698, 1764457, 1775347
Country: ES Centro de información online de medicamentos de la AEMPS Identifier(s): 75095
Country: FR Base de données publique des médicaments Identifier(s): 63941426
Country: PL Rejestru Produktów Leczniczych Identifier(s): 100265853, 100456052, 100462170
Country: TN Direction de la Pharmacie et du Médicament Identifier(s): 15233011
Country: US FDA, National Drug Code Identifier(s): 58914-601

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.